On News of Illumina Bid, Solexa Shares Climb 29 Percent as Illumina's Dive 13 Percent | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Solexa were up 29 percent and shares in Illumina were down 13 percent in midday trading after Illumina said this morning it plans to buy Solexa for roughly $600 million in stocks.
 
Solexa was trading up $2.83 a share at $12.51 while Illumina was trading down $5.75 at $38.28.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.